JP2006515884A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515884A5
JP2006515884A5 JP2006500973A JP2006500973A JP2006515884A5 JP 2006515884 A5 JP2006515884 A5 JP 2006515884A5 JP 2006500973 A JP2006500973 A JP 2006500973A JP 2006500973 A JP2006500973 A JP 2006500973A JP 2006515884 A5 JP2006515884 A5 JP 2006515884A5
Authority
JP
Japan
Prior art keywords
pyridin
fluoro
pyrrolidin
piperidin
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006500973A
Other languages
English (en)
Japanese (ja)
Other versions
JP4613157B2 (ja
JP2006515884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/001069 external-priority patent/WO2004064730A2/en
Publication of JP2006515884A publication Critical patent/JP2006515884A/ja
Publication of JP2006515884A5 publication Critical patent/JP2006515884A5/ja
Application granted granted Critical
Publication of JP4613157B2 publication Critical patent/JP4613157B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006500973A 2003-01-14 2004-01-14 化合物、組成物および方法 Expired - Fee Related JP4613157B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44013303P 2003-01-14 2003-01-14
US44018303P 2003-01-14 2003-01-14
US47608603P 2003-06-04 2003-06-04
US47651703P 2003-06-05 2003-06-05
US50137603P 2003-09-08 2003-09-08
PCT/US2004/001069 WO2004064730A2 (en) 2003-01-14 2004-01-14 Compounds, compositions and methods

Publications (3)

Publication Number Publication Date
JP2006515884A JP2006515884A (ja) 2006-06-08
JP2006515884A5 true JP2006515884A5 (https=) 2006-11-16
JP4613157B2 JP4613157B2 (ja) 2011-01-12

Family

ID=32777326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500973A Expired - Fee Related JP4613157B2 (ja) 2003-01-14 2004-01-14 化合物、組成物および方法

Country Status (11)

Country Link
US (3) US7399866B2 (https=)
EP (2) EP1615878B1 (https=)
JP (1) JP4613157B2 (https=)
KR (1) KR20050100615A (https=)
AT (1) ATE552236T1 (https=)
AU (1) AU2004206860B2 (https=)
CA (1) CA2511970C (https=)
ES (1) ES2387909T3 (https=)
MX (1) MXPA05007513A (https=)
NZ (1) NZ540878A (https=)
WO (1) WO2004064730A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
CA2511970C (en) * 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
US7176222B2 (en) * 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
EP2079831A2 (en) * 2006-11-07 2009-07-22 Keck Graduate Institute Enriched stem cell and progenitor cell populations, and methods of producing and using such populations
KR20100044251A (ko) 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
MX2011002448A (es) * 2008-09-05 2011-05-25 Acucela Inc Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
ES2509951T3 (es) 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011130740A2 (en) 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
US20130288370A1 (en) 2010-10-15 2013-10-31 Cytopherx, Inc. Cytopheresis cartridges and use thereof
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CA2860831C (en) * 2012-01-09 2024-09-10 Seastar Medical, Inc. CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION
US9409868B2 (en) 2012-01-24 2016-08-09 H. Lee Moffin Cancer Center and Research Institute, Inc. Inhibitors of rho associated protein kinases (ROCK) and methods of use
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3115358B1 (en) * 2014-03-04 2019-09-11 ABA Chemicals Corporation Method of preparation and chiral inversion of chiral-1-t-butoxycarbonyl-3-hydroxy piperidine
KR101922542B1 (ko) * 2014-03-21 2018-11-28 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2015142001A2 (ko) * 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
CR20160557A (es) * 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
CA2965467A1 (en) 2014-10-24 2016-04-28 Ono Pharmaceutical Co., Ltd. Kcnq2-5 channel activator
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2018038189A1 (ja) * 2016-08-26 2018-03-01 住友化学株式会社 1-フェニル-3-カルバモイル尿素化合物及びその用途
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
KR101954281B1 (ko) * 2017-09-05 2019-03-05 한국외국어대학교 연구산학협력단 광학적으로 활성인 3-하이드록시피페리딘 또는 이의 유도체의 입체선택적 제조방법
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
JP7610985B2 (ja) * 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814342B1 (en) * 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7447089B2 (ja) 2018-08-31 2024-03-11 サイトキネティックス, インコーポレイテッド 心筋サルコメア阻害剤
CA3144974A1 (en) * 2019-07-17 2021-01-21 Norma TOM Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
TWI867119B (zh) * 2019-12-20 2024-12-21 加拿大商愛彼特生物製藥公司 經取代之雙環和三環脲類及醯胺類、其類似物及使用其之方法
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL254871A (https=) * 1959-08-14
US3128280A (en) * 1959-10-23 1964-04-07 Searle & Co 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas
US4078913A (en) * 1970-04-08 1978-03-14 Tetsuo Takematsu Herbicidal 3-(2-phenylisopropyl)urea derivatives
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
US3939169A (en) * 1971-03-29 1976-02-17 Imperial Chemical Industries Limited Alkylene bis(pyridiniumareylene quaternary salts)
US3994905A (en) * 1974-04-11 1976-11-30 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides
IE47458B1 (en) * 1977-11-07 1984-03-21 Leo Pharm Prod Ltd Quinolylguanidine derivatives
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
DE2942930A1 (de) * 1979-10-24 1981-05-27 Basf Ag, 6700 Ludwigshafen Substituierte harnstoffe, deren herstellung und verwendung als herbizide
DE3147879A1 (de) * 1981-12-03 1983-06-16 Basf Ag, 6700 Ludwigshafen 1,3,5-triazinone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
CA1185974A (en) * 1981-12-03 1985-04-23 Adolf Parg 1,3,5-triazinones and their use for controlling undesirable plant growth
US4672066A (en) * 1985-04-22 1987-06-09 Hoffmann-La Roche Inc. Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5556969A (en) * 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AU7526798A (en) * 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
GB2324798B (en) * 1997-05-01 1999-08-18 Ici Plc Open celled cellular polyurethane products
WO1998052558A1 (en) 1997-05-23 1998-11-26 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
ATE399007T1 (de) 1997-05-23 2008-07-15 Bayer Pharmaceuticals Corp Raf kinase hemmer
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
ES2189238T3 (es) * 1997-11-05 2003-07-01 Choongwae Pharma Corp Nuevo derivado de genipina que tiene actividad protectora del higado.
BR9814375A (pt) 1997-12-22 2002-05-21 Bayer Ag Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
MXPA00006233A (es) * 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
JP3887769B2 (ja) 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害
SK286213B6 (sk) * 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
PE20000564A1 (es) 1998-06-08 2000-07-05 Schering Corp Antagonistas receptores y5 de neuropeptidos
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US6402960B1 (en) * 1999-03-01 2002-06-11 The Regents Of The University Of California Thiacrown polymers for removal of mercury from waste streams
DE19921498A1 (de) * 1999-05-08 2000-11-16 Clariant Gmbh Verfahren zur Herstellung von wäßrigen Diazoniumsalzlösungen
ATE312823T1 (de) * 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
CA2385972A1 (en) 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
GB0015904D0 (en) 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
JP2002220338A (ja) 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するCdk4及び/又はCdk6阻害剤
GB0117950D0 (en) * 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2002092576A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004536845A (ja) * 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003022820A1 (en) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
US7361679B2 (en) 2001-09-12 2008-04-22 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
EP1503986B1 (en) * 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003062235A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
AU2003221322A1 (en) 2002-03-07 2003-09-16 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
KR20040095311A (ko) 2002-03-28 2004-11-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 프로스타글란딘 f 수용체의 모듈레이터로서의 티아졸리딘카르복사미드 유도체
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
PT1499316E (pt) 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
JP2005529890A (ja) 2002-04-23 2005-10-06 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1515940A2 (en) 2002-05-17 2005-03-23 Lica Pharmaceuticals A/S Aminoalkoxy-functional chalcones
WO2004000831A1 (en) 2002-06-24 2003-12-31 Schering Corporation Indole derivatives useful as histamine h3 antagonists
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
CA2493026C (en) 2002-07-31 2011-05-24 Bayer Schering Pharma Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
GB0218147D0 (en) 2002-08-05 2002-09-11 Oxford Glycosciences Uk Ltd Novel compounds
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
WO2004024729A1 (en) 2002-09-10 2004-03-25 Pfizer Products Inc. Diazabicyclic compounds useful in the treatment of cns and other disorders
AU2003285454A1 (en) 2002-10-29 2004-05-25 L'oreal Hair treatment composition containing a styryl-pyrazole compound
CA2511970C (en) * 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
JP5080970B2 (ja) * 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
US7176222B2 (en) * 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
US7672247B2 (en) * 2006-02-23 2010-03-02 International Business Machines Corporation Evaluating data processing system health using an I/O device

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor

Similar Documents

Publication Publication Date Title
JP2006515884A5 (https=)
CA2511970A1 (en) Urea derivatives useful in the treatment of heart failure
ES2742651T3 (es) Compuestos de 3-aminocicloalquilo como inhibidores de ROR-gamma-T y sus usos
ES2672992T3 (es) Compuesto aromático
ES2611604T3 (es) Inhibidores de la c fms quinasa
US7456164B2 (en) 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2014291711B2 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
KR101949624B1 (ko) Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체
AU2018333913B2 (en) Compound having cyclic structure
CN119101049A (zh) 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
EP1747210B1 (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
NZ602141A (en) Inhibitors of semicarabazide-sensitive amine oxidase
BR112020021552A2 (pt) Compostos de 4-aminoisoindolina-1,3-diona substituídos, suas composições e métodos de tratamento com os mesmos
JP2005529092A5 (https=)
AU2007291252A1 (en) Pyridine compounds for treating GPR119 related disorders
HRP20120895T1 (hr) Imidazokinolini sa imuno-modulacijskim svojstvima
RU2012136643A (ru) [5,6]- гетероциклическое соединение
ZA200603941B (en) Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
JP2011512412A5 (https=)
JP2008536825A5 (https=)
CA2626623A1 (en) Method of inhibiting flt3 kinase
RU2014109853A (ru) Соединения для связывания со специфическим для тромбоцитов гликопротеином iib/iiia и их применение для визуализации тромбов
JPWO2020009156A5 (https=)
JP2017523209A5 (https=)
CN109862896A (zh) 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物